BeOne Medicines AG
ONCHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeBeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. At a $40.53B market cap, BeOne Medicines AG ranks as a large-cap company within healthcare. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors.
Market Cap
$40.53B
Beta
0.52
P/E (TTM)
64.09
P/E (Fwd)
34.84
EPS (TTM)
$5.59
EPS (Fwd)
$10.28
ROE
14.7%
ROA
7.5%
Cash
$5.10B
Total Debt
$2.05B
Free CF
$879.0M
52W Change
2.0%
Annual Financials
Cash vs Debt
Where ONC stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, ONC finished 14.28% above its 150-day moving average ($313.84) and 12.77% above its 200-day moving average ($318.05). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ONC overbought or oversold?
At the September 2, 2026 close, ONC's RSI(14) was 49.8, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $5.10B in cash comfortably exceeding the $2.05B debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Annual free cash flow of $879.0M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 14.7% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 7.5% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $1.42B (2022) to $5.34B (2025), reflecting a 277% increase over the period.
ONC's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. At over 50x earnings, ONC carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for BeOne Medicines AG and its sector.